Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 6/2002

01-12-2002 | Meeting report

Workshop on The Epidemiology of the ATMGene: Impact on Breast Cancer Risk and Treatment, Present Status and Future Focus, Lillehammer, Norway, 29 June 2002

Authors: Jonine L Bernstein, Daniela Seminara, Anne-Lise Børresen-Dale

Published in: Breast Cancer Research | Issue 6/2002

Login to get access

Abstract

The role of ataxia-telangiectasia mutated (ATM) heterozygosity in cancer is uncertain. In vitro studies of cells from ATM heterozygotes provide strong evidence of radiation sensitivity. Some, but not all, clinical studies suggest an increased risk of breast cancer among ATM gene carriers, and this risk may be greater among those exposed to radiation. This possible excess risk of breast cancer associated with ATM heterozygosity constitutes the basis for several genetic epidemiological studies designed to clarify the role that the ATM gene plays in the etiology of breast and other cancers. The primary focus of this international, multidisciplinary, National Cancer Institute-sponsored workshop was to discuss ongoing and planned epidemiologic studies aimed at understanding the complexities of the ATM gene and its role in carcinogenesis. The invited participants were from diverse disciplines including molecular and clinical genetics, radiation biology and physics, epidemiology, biostatistics, pathology, and medicine. In the present meeting report, the aims of each project are described.
Literature
1.
Gatti RA, Tward A, Concannon P: Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab. 1999, 68: 419-423. 10.1006/mgme.1999.2942.CrossRefPubMed
2.
Pippard E, Hall A, Barker D, Bridges B: Cancer in homozygotes and heterozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain. Cancer Res. 1988, 48: 2929-2932.PubMed
3.
Borresen A, Andersen T, Tretli S, Heilberg A, Moller P: Breast cancer and other cancers in Norwegian families with ataxia-telangiectasia. Genes Chromosomes Cancer. 1990, 2: 339-340.CrossRefPubMed
4.
Swift M, Morrell D, Massey R, Chase C: Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med. 1991, 325: 1831-1836.CrossRefPubMed
5.
Easton D: Cancer risks in A-T heterozygotes. Int J Rad Biol. 1994, 66: S177-S182.CrossRef
6.
Athma P, Rappaport R, Swift M: Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet. 1996, 92: 130-134. 10.1016/S0165-4608(96)00328-7.CrossRefPubMed
7.
Janin N, Andrieu N, Ossaian K, Lauge A, Croquette M, Griscelli C, Debre M, Bressac-de-Paillertes B, Aurias A, Stoppa-Lyonnet D: Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br J Cancer. 1999, 80: 1042-1045. 10.1038/sj.bjc.6690460.CrossRefPubMedPubMedCentral
8.
Inskip H, Kinlen L, Taylor A, Woods C, Arlett C: Risk of breast cancer and other cancers in heterozygotes for ataxia telangiectasia. Br J Cancer. 1999, 79: 1304-1307. 10.1038/sj.bjc.6690209.CrossRefPubMedPubMedCentral
9.
Shafman TD, Levitz S, Nixon AJ, Gibans LA, Nichols KE, Bell DW, Ishioka C, Isselbacher KJ, Gelman R, Garber J, Harris JR, Haber DA: Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor. Genes Chromosomes Cancer. 2000, 27: 124-129. 10.1002/(SICI)1098-2264(200002)27:2<124::AID-GCC2>3.0.CO;2-M.CrossRefPubMed
10.
Teraoka SN, Malone KE, Doody DR, Suter NM, Ostrander EA, Daling JR, Concannon P: Increased frequency of ATM mutations in breast carcinoma patients with early onset disease and positive family history. Cancer. 2001, 92: 479-487. 10.1002/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G.CrossRefPubMed
11.
Olsen JH, Hahnemann JM, Borresen-Dale AL, Brondum-Nielsen K, Hammarstrom L, Kleinerman R, Kaariainen H, Lonnqvist T, Sankila R, Seersholm N, Tretli S, Yuen J, Boice JD, Tucker M: Cancer in patients with ataxia-telangiectasia and in their relatives in the nordic countries. J Natl Cancer Inst. 2001, 93: 121-127. 10.1093/jnci/93.2.121.CrossRefPubMed
12.
Chenevix-Trench G, Spurdle AB, Gatei M, Kelly H, Marsh A, Chen X, Donn K, Cummings M, Nyholt D, Jenkins MA, Scott C, Pupo GM, Dork T, Bendix R, Kirk J, Tucker K, McCredie MR, Hopper JL, Sambrook J, Mann GJ, Khanna KK: Dominant negative ATM mutations in breast cancer families. J Natl Cancer Inst. 2002, 94: 205-215. 10.1093/jnci/94.3.205.CrossRefPubMed
13.
Angele S, Treilleux I, Taniere P, Martel-Planche G, Vuillaume M, Bailly C, Bremond A, Montesano R, Hall J: Abnormal expression of the ATM and TP53 genes in sporadic breast carcinomas. Clin Cancer Res. 2000, 6: 3536-3544.PubMed
14.
Kairouz R, Clarke RA, Marr PJ, Watters D, Lavin MF, Kearsley JH, Lee CS: ATM protein synthesis patterns in sporadic breast cancer. Mol Pathol. 1999, 52: 252-256.CrossRefPubMedPubMedCentral
Metadata
Title
Workshop on The Epidemiology of the ATMGene: Impact on Breast Cancer Risk and Treatment, Present Status and Future Focus, Lillehammer, Norway, 29 June 2002
Authors
Jonine L Bernstein
Daniela Seminara
Anne-Lise Børresen-Dale
Publication date
01-12-2002
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2002
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr551

Other articles of this Issue 6/2002

Breast Cancer Research 6/2002 Go to the issue

Research article

Breast cancer incidence and mortality trends in an affluent population: Marin County, California, USA, 1990–1999

Commentary

Estrogen–progestin replacement therapy: regulatory action needed

Viewpoint

Mutations in DNA damage response genes and breast cancer susceptibility

Research article

Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer

Review

The importance of being a myoepithelial cell

Review

Progesterone receptors - animal models and cell signaling in breast cancer Diverse activation pathways for the progesterone receptor - possible implications for breast biology and cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits